| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9326752 | Gynecologic Oncology | 2005 | 6 Pages |
Abstract
Patients with mEOC have significantly lower response to first-line platinum-based chemotherapy compared to patients with sEOC. This low response to platinum-based chemotherapy was not translated in inferior TTP or survival. Our data indicate that a new strategy for chemotherapy in mEOC should be adopted, one that focuses on new agents without cross-resistance to platinum agents.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Dimitrios Pectasides, George Fountzilas, Gerasimos Aravantinos, Haralampos P. Kalofonos, Eleni Efstathiou, Emmanouel Salamalekis, Dimitrios Farmakis, Dimosthenis Skarlos, Evangelos Briasoulis, Theofanis Economopoulos, Meletios A. Dimopoulos,